The survival difference between patients with and without deletions narrows with the introduction of imatinib therapy. Kaplan-Meier analysis is shown for survival differences according to deletion status in 2 previously reported cohorts (A)¹⁵  and (B)²⁸  and the cohort in this study to the same scale. No formal comparisons could be made between the 3 groups, but within each group the patients with and without deletions had similar disease characteristics. The median follow-up for each group is comparable. Note that the highly significant difference in survival (analyzed by log-rank test) gradually disappears with the inclusion of more patients treated with imatinib.